9.55
+0.385(+4.20%)
Currency In USD
| Previous Close | 9.16 |
| Open | 9.41 |
| Day High | 9.61 |
| Day Low | 9.15 |
| 52-Week High | 28.18 |
| 52-Week Low | 5.9 |
| Volume | 1.13M |
| Average Volume | 3.52M |
| Market Cap | 988.7M |
| PE | -1.83 |
| EPS | -5.23 |
| Moving Average 50 Days | 8.13 |
| Moving Average 200 Days | 13.69 |
| Change | 0.39 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $431.9 as of May 27, 2025 at a share price of $9.545. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $534.73 as of May 27, 2025 at a share price of $9.545.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
GlobeNewswire Inc.
May 18, 2025 11:25 AM GMT
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline, including in patients who were p
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financi
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
GlobeNewswire Inc.
Apr 03, 2025 11:30 AM GMT
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has bee